RZLT
Rezolute, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.70
+3.35%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -1.7%
- EBIT
- -3.8%
- EPS
- +21.6%
- Free cash flow
- +6.4%
- Operating cash flow
- +6.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +9.3%
- EPS
- +12.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -11.5%
- EBIT
- -3.8%
- Net income
- -4.3%
- EPS
- +23.5%
- Free cash flow
- +6.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026